Harmony Biosciences Holdings, Inc. (HRMY)
Market Cap | 1.85B |
Revenue (ttm) | 582.02M |
Net Income (ttm) | 128.85M |
Shares Out | 56.77M |
EPS (ttm) | 2.13 |
PE Ratio | 15.74 |
Forward PE | 10.88 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 247,673 |
Open | 32.41 |
Previous Close | 32.02 |
Day's Range | 32.21 - 33.62 |
52-Week Range | 18.61 - 39.27 |
Beta | 0.72 |
Analysts | Buy |
Price Target | 43.78 (+30.61%) |
Earnings Date | Apr 30, 2024 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Har... [Read more]
Financial Performance
In 2023, HRMY's revenue was $582.02 million, an increase of 32.93% compared to the previous year's $437.86 million. Earnings were $128.85 million, a decrease of -28.99%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $43.78, which is an increase of 30.61% from the latest price.
News
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upco...
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa. , Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming inves...
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
Prescription Drug User Fee Act date is June 21, 2024 PLYMOUTH MEETING, Pa., Feb. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Admini...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa. , Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation ...
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
PLYMOUTH MEETING, Pa. , Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thursd...
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
WAKIX® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter and ~$582 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively Average Number of Patients on ...
HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , Jan. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
PLYMOUTH MEETING, Pa. , Dec. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal det...
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
PLYMOUTH MEETING, Pa. , Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...
Why these stocks could lose money even if the market gains
According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , Nov. 16, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi...
HARMONY BIOSCIENCES RANKED AMONG TOP 25 FASTEST-GROWING COMPANIES IN NORTH AMERICA ON THE 2023 DELOITTE TECHNOLOGY FAST 500™
PLYMOUTH MEETING, Pa. , Nov. 15, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi...
HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS
PLYMOUTH MEETING, Pa. , Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year
HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS
PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative ther...
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023
PLYMOUTH MEETING, Pa. , Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi...
HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., Oct. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™...
HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa. , Oct. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that...
HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D.
PLYMOUTH MEETING, Pa. , Sept. 20, 2023 /PRNewswire/ -- Jeffrey M.
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializ...
HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa. , Sept. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the...
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Pharmace...